In Jan 2020 Professor Mary O'Brien (Consultant Medical Oncologist, Royal Marsden) joined as Chair of our Medical Advisory Board.
She is in the process of putting together her team.
On 14th Feb 2020, Professor Loic Lang-Lazdunski joined the board alongside Dr Andrew Furness.
See below for Board Biographies.
They will be meeting with a number of research teams/projects to decide where the money will be best spent.
We are hoping to fund a number of leading-edge research projects in future.
We will keep you posted as to exactly where the money has gone and what we have achieved with your donations and support.
Thank you for your generosity and support.
Professor Mary O'Brien
Professor Mary O’Brien is a well know thoracic medical oncologist with a vast experience of research and over 250 publications. She has a long interest in mesothelioma and has been involved in some of the earliest randomised studies.
She comes to the advisory board with enthusiasm and knowledge.
‘The challenge is great, and so should be the effort in research at this point.
Long years of difficult research is now delivering new approaches and treatments that will make a difference to our patients – we want to influence and be part of this’.
Professor Loic Lang-Lazdunski
MD PhD FRCS(Eng)
Consultant Thoracic Surgeon
Professor Lang-Lazdunski qualified in 1991 and trained in general surgery and cardiothoracic surgery in the Paris rotation, France.
He was recruited as a consultant thoracic surgeon at Guy's Hospital in 2003 and promoted to Professor of Thoracic surgery in 2012.
He has developed and currently leads one of the largest mesothelioma programs in Europe.
He is a world-renowned expert in minimally invasive thoracic surgery and complex thoracic surgery.
Dr Andrew Furness
Andrew completed his undergraduate medical training at Guy’s, King’s and St Thomas’ School of Medicine, London; where he also undertook an intercalated BSc in Human Physiology.
Following completion of core training in internal medicine, he undertook specialist training in Medical Oncology at The Royal Marsden under the mentorship of Professor Martin Gore.
In 2013, he was awarded the Sam Keen Foundation Fellowship and spent four years studying Cancer Immunology at University College London Cancer Institute. During this time he studied the immune landscape of human tumours and made fundamental contributions to current understanding of the mechanisms underlying the activity of immune-modulatory antibody-based therapies; he was awarded a PhD in 2018.
His findings have been published in high impact journals including Cancer Cell, Immunity and Science and his efforts have been recognised with a number of awards including the Association of Cancer Physicians McElwain Prize and Cancer Research UK Translational Research Prize.
In 2019, he was appointed as a Consultant in Medical Oncology and Solid Tumour Cell Therapy lead. He is currently a faculty member of the ESMO Tumour Immunology and Immunotherapy group, sits on the ESMO Precision Medicine and Translational research working group and the scientific committee for this year’s Immuno-Oncology Congress in Geneva.
His research interests are centred in translational immunology and the clinical application of cell therapy for solid tumours.